These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17501698)

  • 41. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
    Dey N; De P; Leyland-Jones B
    Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
    Li H; Zeng J; Shen K
    Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
    Herschbein L; Liesveld JL
    Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genomic profiling of small-cell lung cancer: the era of targeted therapies.
    Umemura S; Tsuchihara K; Goto K
    Jpn J Clin Oncol; 2015 Jun; 45(6):513-9. PubMed ID: 25670763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
    Lieu C; Kopetz S
    Clin Colorectal Cancer; 2010 Apr; 9(2):89-94. PubMed ID: 20378502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer: survival pathways meet their end.
    McCormick F
    Nature; 2004 Mar; 428(6980):267-9. PubMed ID: 15029179
    [No Abstract]   [Full Text] [Related]  

  • 57. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
    Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
    Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging therapeutic targets in non-small cell lung cancer.
    Dy GK; Adjei AA
    Proc Am Thorac Soc; 2009 Apr; 6(2):218-23. PubMed ID: 19349491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through Src-like tyrosine kinases and PI3K/Akt pathways.
    Cui QL; Fogle E; Almazan G
    Neurochem Int; 2006 Apr; 48(5):383-93. PubMed ID: 16439036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.